71 results about "Sjogrens syndrome" patented technology

The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor CXCR5. The CXCR5 receptor compounds are derived from the intracellular loops and domains of the CXCR5 receptor. The invention also relates to the use of these CXCR5 receptor compounds and pharmaceutical compositions comprising the CXCR5 receptor compounds in the treatment of diseases and conditions associated with CXCR5 receptor modulation such as autoimmune diseases including lupus, HIV and rheumatoid arthritis, Primary Sjogren's Syndrome, chronic lymphocytic leukemia, Burkitt Lymphoma, colon and breast cancer tumor metastasis, Multiple Sclerosis and compromised immune function.

The invention relates to screen for antigen epitope polypeptide, and building up of immunology detection method and the manufacturing and application for reagent for clinical diagnosis, especially for alpha-cyst albumen antigen epitope polypeptide.

The present invention provides methods and compositions involving epigenetic and gene expression signatures and their association with Sjögren's syndrome.

Described herein is the finding that patients with Sjögren's syndrome exhibit a statistically significant increase in expression of BMP6 in the salivary gland, relative to healthy control subjects. Also described herein is the finding that overexpression of BMP6 in the salivary glands of mice results in an increase in electrical potential across the salivary gland. Thus, provided herein are methods of diagnosing a subject as having Sjögren's syndrome, or at risk for developing Sjögren's syndrome, by measuring the level of BMP6 expression in a salivary gland of a subject, measuring electrical potential in a salivary gland of a subject, or both. Also provided herein are methods of treating a subject with Sjögren's syndrome by administering an agent that inhibits expression of BMP6 expression or activity. Also described herein is the use of XIST and MECP2 as diagnostic and therapeutic targets for male Sjögren's syndrome patients.

The invention relates beta-fordin antigen epitope polypeptide screening for gaining amino acid sequence corresponded with the optimum beta-fordin polypeptide. The beta-fordin antigent epitope polypeptide includes the following two that one is formed by the amino acid sequence showed in SEQ ID NO.1; another is derived from the above amino acid sequence by replacing, missing or adding one or many amino acid with antigen epitope function. It can used to specially test beta-fordin polypeptide IgG antibody for Sjogren syndrome patient. The invention also supplies the beta-fordin polypeptide IgG antibody immunology method, and its application used as antigen in Sjogren syndrome medicine preparation.

The invention provides a compound for use in treating or preventing a disease or condition selected from cystic fibrosis, chronic obstructive pulmonary disease (COPD), asthma, mild pulmonary disease, bronchitis, bronchiectasis, idiopathic bronchiectasis, allergic bronchopulmonary aspergillosis, sinusitis, rhinosinusitis, CFTR-related metabolic syndrome (CRMS), pancreatitis, idiopathic chronic pancreatitis and Sjörgren's syndrome, or for use in preventing male infertility caused by congenital absence of the vas deferens, in a patient by modulating CFTR activity, which compound is 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one or a pharmaceutically acceptable acid addition salt thereof. The invention also provides a composition comprising (i) 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one or a pharmaceutically acceptable acid addition salt thereof and (ii) a leukotriene receptor antagonist. The invention also provides a composition comprising (i) 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one or a pharmaceutically acceptable acid addition salt thereof and (ii) a CFTR potentiator or a CFTR corrector.

Methods of treating lupus, including systemic lupus erythematosus, cutaneous lupus erythmetosus, and lupus nephritis, are provided. The methods involve administration of a combination of a non-depleting CD4 antibody and another compound used clinically or experimentally to treat lupus. Methods of treating lupus nephritis by administration of a non-depleting CD4 antibody that results in an improvement in renal function and/or a reduction in proteinuria or active urinary sediment are also provided. Methods of treating lupus or decreasing autoantibody titer by administration of a non-depleting CD4 antibody are also provided. Methods of treating multiple sclerosis by administration of a non-depleting CD4 antibody, optionally in combination with another compound used clinically or experimentally to treat MS, are described. Methods of treating transplant recipients and subjects with rheumatoid arthritis, asthma, psoriasis, Crohn's disease, ulcerative colitis, and Sjogren's syndrome are also provided.

The present disclosure provides a method for treating lupus, Sjogren's syndrome or scleroderma, the method comprising administering to the mammal an immunoglobulin which binds an interleukin 3 receptor alpha (IL-3R alpha) chain and which depletes or at least partly eliminates plasmacytoid dendritic cells (p DCs) and basophils to which it binds.

The present invention provides one kind of alpha-fodrin polypeptide and its analog used for the detection of xerosis syndromes. This kind of polypeptide antigen may be combined specifically with the specific antibody in the body of xerosis syndromes patient and has very high sensitivity and specificity.

The invention relates to a method, compounds and compositions for the secondary prevention, treatment or dietary management of symptomatic and asymptomatic non-intestinal autoimmune diseases in a non-infant human including Sjogren's syndrome and type 1 diabetes. Said method, compounds and compositions for the secondary prevention, treatment or dietary management include human milk oligosaccharide (HMO), preferably mixtures of human milk oligosaccharides selected from the group of 2′-FL, LNnT, LNT, DFL, and 6′-SL.

The present invention provides small-molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to treat subjects with Sjögren's syndrome, or diffuse intrinsic pontine glioma (DIPG).

The invention discloses a medicinal composition for treating sjogren syndrome and a preparation method thereof and an application. The medicinal composition is prepared from components including the following raw materials; 15-25 parts by weight of radix rehmanniae, 20-30 parts by weight of radix scrophulariae, 15-25 parts by weight of radix ophiopogonis, 25-35 parts by weight of radix paeoniae alba, 5-15 parts by weight of radix glycyrrhizae, 15-25 parts by weight of mulberry leaves, 10-20 parts by weight of flos chrysanthemi, 10-20 parts by weight of fructus aurantii, 15-25 parts by weight of fructus ligustri lucidi, 25-35 parts by weight of radix puerariae, and 15-25 parts by weight of caulis sinomenii. The medicinal composition of the present invention has significant effect on treating sjogren syndrome.

The invention relates to a pharmaceutical composition comprising lysozyme, dextranase and an essential oil of a plant belonging to the family Myrtaceae. The composition is preferably formulated, together with other ingredients, as a mouthwash.

The invention also relates to a method for the prevention, treatment and follow-up of pathologies of the oral cavity of infectious, inflammatory, degenerative or autoimmune origin, the method comprising the administration of the composition of the invention to a patient affected by one or more of such pathologies, which are preferably selected in the group consisting of: gingivitis, periodontitis, aphthous stomatitis, herpetic stomatitis, prosthetic stomatitis, recurrent aphthosis, xerostomia, xerostomia due to Sjogren's syndrome, burning mouth syndrome (BMS), oral candidiasis, inflammatory dermatoses such as oral lichen planus, autoimmune disorders of the mucous membranes such as mucous membrane pemphigoid (MMP), graft-versus-host disease, white tongue, migratory glossitis, desquamative gingivitis due to oral lichen planus, herpes and combinations thereof.

The invention relates to a novel treatment method for dry eyes, i.e. treatment of dry eyes by tacrolimus with a concentration of 0.02%-0.03%. Directed at the current situation of clinical absence of effective methods for treatment of dry eyes, the invention aims to provide an effective measure with low side effect to treat dry eyes. Specifically, tacrolimus with a concentration of 0.02%-0.03% is applied four times per day for one month continuously so as to treat chronic non-sjogren syndrome related dry eyes.

The present invention provides compositions and methods for the treatment of Sjogren's syndrome (SS) and SS-related symptoms in human subjects by synthetic peptides based on the sequence of CDR1 of an anti-DNA monoclonal antibody.

The invention provides a check of Sjogren syndrome by M3-type receptor protein polypeptide and analogues, wherein the peptide antigen can be specially combined with specific antibody in Sjogren syndrome patient, with high sensitivity and specificity.

The present invention relates to compounds of Formula I,

The invention provides an M3 receptor altered peptide and an analogue thereof, which are used for detecting the sjogren syndrome. An antigen of the altered peptide can be specifically combined with a specific antibody in a patient with the sjogren syndrome, thereby having very high sensitivity and specificity.